Utah Doctor's DEA License Revoked for Risky Opioid Prescriptions
Published Date: 1/15/2026
Notice
Summary
Dr. Jason Vanshaar from Utah had his DEA license suspended and is facing revocation because he prescribed lots of strong drugs in unsafe ways, risking public health. This affects him directly and means he can’t legally prescribe controlled substances anymore. The decision is final as of early 2026, stopping him from getting new DEA registrations and protecting patients from harm.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked
The Drug Enforcement Administration revoked Jason VanShaar, M.D.'s DEA Certificate of Registration No. FV2721694 and denied his pending application No. W24166810C. The Order also denies any other pending applications he submitted in Utah or Arizona; the revocation is effective February 17, 2026.
Immediate Suspension Began May 28, 2025
On May 28, 2025 the DEA issued an Order to Show Cause and an Immediate Suspension of Registration for Jason VanShaar, M.D., suspending his DEA registration (No. FV2721694) pending final agency action. That suspension removed his ability to hold an active DEA registration beginning with the May 28, 2025 suspension.
Findings: Dangerous Prescribing; Patient Protection
The DEA found that from at least February 2021 to at least March 2025 the registrant issued at least 288 prescriptions for Schedule II–IV controlled substances to four patients, including many 'Holy Trinity' opioid/benzodiazepine/carisoprodol combinations that increase overdose risk. The agency stated the action (suspension and revocation) was taken to protect the public health and safety.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
Previous / Next Documents
Previous: 2026-00626, Walter Walters, M.D.; Decision and Order
Dr. Walter Walters from Indiana lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. Despite multiple attempts, he didn’t respond or ask for a hearing, so the DEA officially revoked his certificate. This means he can’t prescribe or manage controlled drugs anymore, effective immediately, impacting his medical practice and patients.
Next: 2026-00629, Pine Pharmacy; Decision and Order
Pine Pharmacy in Florida lost its DEA registration because it filled risky prescriptions without proper checks and let unauthorized people order controlled drugs. This means Pine Pharmacy can no longer legally handle certain medicines, protecting public safety. The change is effective immediately, so patients and the pharmacy must adjust fast.